Business Context and Reporting Period
Company: Stryker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: Stryker operates in two primary segments: Orthopaedic Implants (reconstructive, trauma, and spinal implants) and MedSurg Equipment (powered surgical instruments, endoscopic systems, and hospital beds). The company also reports Physical Therapy Services and corporate administration under "Other."
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2001 |
|---|---|---|---|
| Net Sales | $745.6 | $2,182.4 | $1,892.5 |
| Gross Profit | $465.7 | $1,380.5 | $1,194.1 |
| Gross Margin | 62.5% | 63.3% | 63.1% |
| Net Earnings | $72.5 | $239.5 | $190.4 |
| Diluted EPS | $0.36 | $1.18 | $0.94 |
| Operating Cash Flow | $148.0 | $320.8 | $285.1 |
| Cash and Equivalents | $38.7 | $38.7 | $50.1 (Dec 31, 2001) |
| Total Debt (Long-term + Current) | $616.8 | $616.8 | $722.6 (Dec 31, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20% in the third quarter and 15% for the nine-month period compared to 2001. Growth was driven by increased unit volume, favorable product mix, and the July 1, 2002, acquisition of Surgical Dynamics (SDI).
- Profitability: Net earnings rose 20% in the quarter and 26% year-to-date. This growth occurred despite a $17.2 million restructuring charge in the third quarter.
- Cost Structure: Cost of sales as a percentage of sales increased slightly in the quarter (37.5% vs. 36.9% in 2001) due to product obsolescence from new launches, partially offset by higher absorbed manufacturing costs.
- Debt Reduction: Total borrowings declined by $105.8 million during the first nine months of 2002, despite borrowing $384.3 million to fund operations and the SDI acquisition.
- Accounting Changes: The company adopted FASB Statement No. 142, eliminating goodwill amortization. If applied to 2001, prior year net earnings would have been higher by $9.3 million for the nine-month period.
Guidance, Outlook, and Risks
- Restructuring Activity: A $21.0 million charge was recorded to close the Rutherford, New Jersey manufacturing facility. Approximately 400 employees are affected, with severance payments expected to extend into 2004. Production is transitioning to Mahwah, NJ, and facilities in Ireland.
- Acquisitions: The $135.0 million acquisition of SDI expanded the spinal product line. Integration is underway, including workforce reductions of 37 SDI employees.
- Subsequent Event: On October 1, 2002, Stryker paid $14.0 million to Curis, Inc., to eliminate future royalties on OP-1 sales. This amount will be amortized over 15 years.
- Liquidity: The company maintains $472.9 million in available borrowing capacity. Management believes cash on hand and operating cash flows are sufficient to fund future activities and debt repayments.
- Risks: Forward-looking statements are subject to risks including regulatory cost-containment measures, changes in third-party reimbursement levels, product liability claims, and foreign exchange fluctuations.
Investor Verification Checklist
- Restructuring Costs: Verify the timeline and total cost of the Rutherford facility closure and the integration of SDI.
- Goodwill Impairment: Monitor future annual impairment tests under FASB 142, as goodwill is no longer amortized but subject to write-downs.
- Debt Covenants: Review credit facility terms given the recent borrowing activity to fund the SDI acquisition and working capital needs.
- Foreign Currency Impact: Assess the volatility of international sales (13% of total) and the impact of exchange rate fluctuations on reported earnings.
- Product Mix: Confirm the sustainability of the "favorable product mix" cited as a driver of revenue growth, particularly in the Orthopaedic Implants segment.